T9G.F Vidac Pharma Holding Plc

Healthcare Biotechnology Frankfurt Exchange
0.2080 EUR
Close of Nov 12, 2026
0.1300 0.6280
Market cap
EUR 11.8M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is T9G.F undervalued?

Graham number

The Graham number of Vidac Pharma Holding Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vidac Pharma Holding Plc fundamental analysis

No fundamental analysis for Vidac Pharma Holding Plc yet.

Vidac Pharma Holding Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vidac Pharma Holding Plc

Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of anticancer medicines. The company is developing VDA-1102 CTCL which is in phase 2 clinical trials for the treatment of cutaneous T cell lymphoma (CTCL); and VDA-1102 Ointment, an anti-neoplastic agent that is in phase 2B clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplas…

Full company profile